StockData
Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc. (HRMY) stock

HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)

Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –

Harmony Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Harmony Biosciences's operating income for the twelve months ending Jun 30, 2026 was $230.65M, up 4.0% year over year. For fiscal 2025 it was $208.47M, up 9.2% from the year before. The highest annual figure on record is $208.47M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$208.47M+9.2%
FY2024Dec 31, 2024$190.83M-0.6%
FY2023Dec 31, 2023$192.03M+59.8%
FY2022Dec 31, 2022$120.19M+37.3%
FY2021Dec 31, 2021$87.53M+415.3%
FY2020Dec 31, 2020$16.99M–
FY2019Dec 31, 2019-$145.90M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$89.32M+85.4%
Q1 FY2026Mar 31, 2026$37.29M-33.7%
Q4 FY2025Dec 31, 2025$38.56M-30.8%
Q3 FY2025Sep 30, 2025$65.49M+6.1%
Q2 FY2025Jun 30, 2025$48.18M+125.6%
Q1 FY2025Mar 31, 2025$56.25M+8.1%
Q4 FY2024Dec 31, 2024$55.73M+38.6%
Q3 FY2024Sep 30, 2024$61.71M-4.3%
Q2 FY2024Jun 30, 2024$21.36M-54.5%
Q1 FY2024Mar 31, 2024$52.03M+28.7%
Q4 FY2023Dec 31, 2023$40.20M-15.6%
Q3 FY2023Sep 30, 2023$64.51M+442.0%
Q2 FY2023Jun 30, 2023$46.90M+41.6%
Q1 FY2023Mar 31, 2023$40.42M+46.7%
Q4 FY2022Dec 31, 2022$47.61M+66.3%
Q3 FY2022Sep 30, 2022$11.90M-43.5%
Q2 FY2022Jun 30, 2022$33.12M+42.1%
Q1 FY2022Mar 31, 2022$27.56M+89.6%
Q4 FY2021Dec 31, 2021$28.63M+269.1%
Q3 FY2021Sep 30, 2021$21.05M+102.8%
Q2 FY2021Jun 30, 2021$23.31M+218.9%
Q1 FY2021Mar 31, 2021$14.53M–
Q4 FY2020Dec 31, 2020$7.76M–
Q3 FY2020Sep 30, 2020$10.38M–
Q2 FY2020Jun 30, 2020$7.31M–
Q1 FY2020Mar 31, 2020-$9.61M–
Q4 FY2019Dec 31, 2019-$33.69M–
Q3 FY2019Sep 30, 2019-$29.80M–

More Harmony Biosciences figures

See a number that looks wrong?